Harrow's IHEEZO Demonstrates Patient Comfort Benefit In Intravitreal Study

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

Royce & Associates LP reduced its Harrow, Inc. (NASDAQ:HROW) stake by 4.4% in Q4, selling 23,267 shares to hold 509,746 shares worth about $24.98M, per its SEC disclosure. Harrow reported May 11 EPS of -$0.74 vs -$0.43 consensus and revenue of $44.2M vs $52.43M. Analysts’ average target is $69.43.

Radiopharm Theranostics (RADX) announced its Phase 1 HEAT trial for 177Lu-RAD202 will advance to Cohort 4 at a higher 180mCi dose level, per the Data Safety and Monitoring Committee's recommendation. The trial, evaluating RAD202 for HER2-positive advanced solid tumors, previously used a 130mCi dose. RADX stock closed at $2.50, up 1.20% in pre-market trading.